Huang Jun, Wang Meng-Hong, Peng Xiao-Ping, Wei Chunying, Lu Jun
Department of Cardiology, the First Hospital Affiliated to Jiangri Medical College, Nanchang (330006).
Zhongguo Zhong Xi Yi Jie He Za Zhi. 2006 Mar;26(3):221-3.
To investigate the effects of Xuezhikang (XZK) on serum levels of high sensitivity-C reactive protein (Hs-CRP), matrix metalloproteinase-9 (MMP-9) and lipoprotein in patients with acute coronary syndrome (ACS).
Sixty-nine ACS patients were divided into the XZK group (40 cases) treated with conventional therapy and XZK and the control group (29 cases) with conventional therapy alone, another 30 healthy persons were assigned as the normal group. Before and after the treatment, the levels of Hs-CRP, MMP-9 and lipids were detected.
Compared with those in the normal subjects, Hs-CRP and MMP-9 levels in the ACS patients increased significantly (P <0.05), parallel with the extent of myocardial injury. After 2 weeks of XZK treatment, levels of Hs-CRP and MMP-9 of the XZK group decreased significantly (P <0.05), while lipids levels had no remarkable changes.
Hs-CRP and MMP-9 levels were closely correlated to the genesis and severity of ACS. Anti-inflammatory action of XZK plays an important role in early stage treatment of ACS patients.
探讨血脂康（XZK）对急性冠状动脉综合征（ACS）患者血清高敏C反应蛋白（Hs-CRP）、基质金属蛋白酶-9（MMP-9）水平及脂蛋白的影响。
将69例ACS患者分为血脂康组（40例），采用常规治疗加血脂康；对照组（29例）仅采用常规治疗，另选取30例健康者作为正常组。治疗前后检测Hs-CRP、MMP-9水平及血脂。
与正常受试者相比，ACS患者的Hs-CRP和MMP-9水平显著升高（P<0.05），与心肌损伤程度平行。血脂康治疗2周后，血脂康组的Hs-CRP和MMP-9水平显著降低（P<0.05），而血脂水平无明显变化。
Hs-CRP和MMP-9水平与ACS的发生及严重程度密切相关。血脂康的抗炎作用在ACS患者的早期治疗中起重要作用。
